Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting.

Liu Y, Chen J, Zhong H, Yu Y, Liu S, Yu Y

Open source

DOI
10.3389/fphar.2026.1895524
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1895524,
  title = {Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting.},
  author = {Liu Y and Chen J and Zhong H and Yu Y and Liu S and Yu Y},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1895524},
  url = {https://doi.org/10.3389/fphar.2026.1895524}
}

RIS

TY  - JOUR
TI  - Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting.
AU  - Liu Y
AU  - Chen J
AU  - Zhong H
AU  - Yu Y
AU  - Liu S
AU  - Yu Y
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1895524
UR  - https://doi.org/10.3389/fphar.2026.1895524
ER  - 

APA

Y, L., J, C., H, Z., Y, Y., S, L., & Y, Y. (2026). Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1895524

Source records